Global Artemisinin Combination Therapy Market Opportunities and Forecast 2023-2030

Artemisinin Combination Therapy Market Overview

There has been an incredible upsurge in the demand for artemisinin combination medical care (ACT) over the past few years following its recognition as first-line treatment for protozoal infection by the planet Health Organization.ACTs are the foremost effective antimalarial medicines offered nowadays. Currently, the UN agency recommends half dozen ACTs for the treatment of protozoal infection. In recent years, access to them has inflated significantly. By 2016, they were adopted as first-line treatment in virtually eighty countries. Their edges embody quick action, high effectualness, and reduced chance of developing resistance.The pipeline for new antimalarial drugs is rising and some of them are introduced recently. a number of the new ACTs, that are registered and utilized in some countries, are arterolane-piperaquine, artesunate-pyronaridine, artemisinin-piperaquine base, and artemisinin-naphthoquinone.

Rising R & D activities and rising medical infrastructure, in the main in developing economies together with India and China, square measure stimulating the expansion of the market. Increasing demand from malaria-endemic countries like African nation, Nigeria, Congo, and alternative South-East Asian countries is probably going to drive the market throughout the forecast period.

Report Metric	Details
Market size available for years	2023–2030
Base year considered	2023
Forecast period	2024–2030
Forecast unit	Value (USD Million)
Segments covered	Type, Distribution Channel, and Region
Regions covered	North America (the U.S. and Canada), Europe (UK, Germany, France, Italy, Spain, Russia, Rest of Europe), Asia-Pacific (China, India, Japan, Australia, South East Asia, Rest of Asia Pacific), Latin America and the Middle East and Africa (Brazil, Saudi Arabia, UAE, Rest of LAMEA)
Companies covered	Novartis, Sanofi, Cipla, Ajanta Pharma, Ipca Laboratories, Guilin Pharmaceuticals, and KPC Pharmaceuticals.

The covid-19 Impact on Artemisinin Combination Therapy Market:

Whereas, the chemicals and accouterments sectors were relatively affected during the pandemic. This is primarily due to uncut demand for chemicals for healthcare, life wisdom, and drawing agents. However, other elements of chemical and material sectors such as types of paints, industrial oil, construction materials are facing reduction in demand. Strict lockdown reflected in a nearly 50-60% reduction in force for raw supply and availability, which directly affected the manufacturing process. Further, halt on numerous end-use diligence directly affected the chemical demand each around the world.
 
Artemisinin Combination Therapy market Segment Overview



By Type, There are presently 6 ACTs available, that segment artemether+lumefantrine (AL), artesunate+amodiaquine, artesunate+mefloquine (AS+MQ), Dihydroartemisinin+piperaquine (DHA PPQ), artesunate+sulfadoxine-pyrimethamine (AS+SP), and pyronaridine-artesunate (PA). AL was the largest phase in 2017.
 
By Distribution Channel , hospital pharmacies is increasing across the world, owing to development in infrastructural and facilities. 
 
Market Analysis, Insights and Forecast – By Type
·       Artemether+Lumefantrine
·       Artesunate+Amodiaquine
·       Dihydroartemisinin+Piperaquine
·       Artesunate+Mefloquine
·       Artesunate+Sulfadoxine-Pyrimethamine
·       Pyronaridine-Artesunate

Market Analysis, Insights and Forecast – By Distribution Channel
·       Hospital Pharmacies
·       Retail Pharmacies
·       Online Pharmacies
·       Others

Artemisinin Combination Therapy Market Regional Overview

Region-wise, in terms of regions ,The Middle East and Africa held the largest share within the artemisinin combination contributing market in 2017. The presence of a large production base of artemisinin herbs and rising demand in malaria-endemic countries are tributary to the expansion of the market in MEA and also the Asia Pacific. tho' African countries, wherever the incidence of malaria is that the highest, have accrued malaria management methods, effective treatment, and management, it still presents an enormous supplying issue. As many at-risk individuals board extreme economic condition in remote areas, WHO and different organizations ar working on completely eradicating it in continent, and thus, over the approaching years, the adoption rate of ACT is any expected to extend.

 Artemisinin Combination Therapy Market, By Geography

·       North America (US & Canada)
·       Europe (UK, Germany, France, Italy, Spain, & Rest of Europe)
·       Asia-Pacific (Japan, China, India, Australia, & South Korea, & Rest of Asia-Pacific)
·       LAMEA (Brazil, Saudi Arabia, UAE & Rest of LAMEA)
 
Artemisinin Combination Therapy Market Competitor overview

Some key developments and strategies adopted by manufacturers in the Artemisinin Combination Therapy are highlighted below.
·       In 2021, Novartis and Medicines for protozoal infection Venture have reported positive results from the part IIb study, evaluating a new non-artemisinin combination to treat uncomplicated malaria in children.

Artemisinin Combination Therapy Market, Key Players -

·       Novartis,
·       Sanofi,
·       Cipla,
·       Ajanta Pharma,
·       Ipca Laboratories,
·       Guilin Pharmaceuticals,
·       KPC Pharmaceuticals.

Frequently Asked Questions (FAQ) :

Q1. What is the total CAGR expected to be recorded for the Artemisinin Combination Therapy Market during the forecast period?

Q2. Which segment is projected to hold the largest share in the Artemisinin Combination Therapy Market?

Q3. What are the driving factors for the Artemisinin Combination Therapy Market?

Q4. Which Segments are covered in the Artemisinin Combination Therapy Market report?

Q5. Which are the prominent players offering Artemisinin Combination Therapy Market?